Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Roche's (RHHBY) Lunsumio Application Gets Priority Review
05:17pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
Roche's (RHHBY) BLA application seeking approval for the use of Lunsumio for relapsed or refractory follicular lymphoma has been granted priority review in the United States.
Here's Why You Should Retain Edwards Lifesciences (EW) Now
05:15pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
Investors are optimistic about Edwards Lifesciences' (EW) strong segmental performance and the growing demand for its RESILIA tissue valves.
Reasons Why You Should Invest in ResMed (RMD) Stock Now
05:04pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
Investors are optimistic about ResMed's (RMD) robust mask and device sales and continued product innovations.
Bokeh's Kim Forrest on how investors can position themselves in choppy market
03:02pm, Wednesday, 06'th Jul 2022
Kim Forrest, Bokeh Capital Partners chief investment officer, joins 'The Exchange' to discuss the economy and markets.
Tandem Diabetes (TNDM) New Launches Aid Growth Amid Cost Woes
01:13pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Bruker (BRKR) International Growth Strong Amid Competition
01:03pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
Bruker (BRKR) Nano Group's microelectronics and semiconductor metrology tools continue to perform well with ongoing strength in bookings and backlog.
Jim Cramer picks 7 Dow stocks that investors should consider owning
06:52pm, Tuesday, 05'th Jul 2022
Companies in the Dow "tend to be boring, mature companies that typically pay nice dividends," the "Mad Money" host said.
Here's Why Investors Should Retain Charles River (CRL) Now
04:56pm, Tuesday, 05'th Jul 2022 Zacks Investment Research
Investors are optimistic about Charles River's (CRL) strong segmental growth and notable collaborations.
ChemoCentryx's (CCXI) Tavneos Aids Growth, Overdependence a Woe
04:53pm, Tuesday, 05'th Jul 2022 Zacks Investment Research
ChemoCentryx (CCXI) has only one product approved for sale in its portfolio, Tavneos. Nevertheless, it is progressing well with the clinical development of its pipeline candidates.
What Stocks To Buy Today? 5 Health Care Stocks To Know
04:30pm, Tuesday, 05'th Jul 2022
Could health care stocks be the best stocks to jump on in the second half of 2022?
Corcept (CORT) Thrives on Korlym Amid Overdependence Concerns
03:14pm, Tuesday, 05'th Jul 2022 Zacks Investment Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.
Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?
03:09pm, Tuesday, 05'th Jul 2022 Zacks Investment Research
Exelixis (EXEL) outperforms the industry in the year so far on Cabometyx performance and pipeline progress.
AstraZeneca (AZN) to Buy TeneoTwo, Boost Hematology Pipeline
02:16pm, Tuesday, 05'th Jul 2022 Zacks Investment Research
AstraZeneca's (AZN) acquisition of TeneoTwo is set to add an early-stage T-cell engager to AZN's pipeline. The transaction is likely to close by third-quarter 2022.
3rd-Quarter Clinical Trial Data Could Shake Up Pharma Stocks
11:43am, Tuesday, 05'th Jul 2022
Health care investors would be wise to keep tabs on the results of numerous drug trials scheduled to be revealed in the third quarter. Trial data can impact the stock price of a pharmaceutical company
6 Recession-Proof Stocks to Buy as the Market Boom Ends
11:11am, Tuesday, 05'th Jul 2022
These stocks pay dividends, have low payout ratios, low P/E multiples, and good growth. These six stocks are in industries and fields that make them recession-proof stocks, especially given their divi
